Market news — every asset we track

Assets

SCNI

Scinai regains compliance with Nasdaq minimum bid price rule

Sep 21Investing.com

SCNI

12 Health Care Stocks Moving In Monday's Intraday Session

Sep 14Benzinga

EUDA

SCNI

Nasdaq Down Over 200 Points; Cellectis Shares Plunge

Sep 14benzinga.com

CLLS

SCNI

12 Health Care Stocks Moving In Monday's Pre-Market Session

Sep 14benzinga.com

SCNI

12 Health Care Stocks Moving In Friday's After-Market Session

Sep 11Benzinga

SCNI

Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business

Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company combining innovative immunology therapeutic development with a revenue-generating contract development and manufacturing organization ("CDMO"), today announced a strategic refocusing of its R&D portfolio following the conclusion of its option and license arrangements with PinCell S.r.l. relating to PC111.

Sep 8Yahoo Finance

SCNI

Earnings call transcript: Scinai posts H1 2026 revenue growth as losses persist

Aug 26Investing.com

SCNI

Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum

Aug 24Yahoo Finance

SCNI

Scinai reports H1 2026 results, announces U.S. customer expansion

Aug 24Investing.com

SCNI

Scinai Immunotherapeutics Sets 1-for-10 ADS Ratio Change to Support Nasdaq Compliance